K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 38.2 HKD -3.29% Market Closed
Market Cap: 10.5B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

KeyMed Biosciences Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Common Shares Outstanding
ÂĄ279.7m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Common Shares Outstanding
ÂĄ1.4B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Common Shares Outstanding
ÂĄ1.3B
CAGR 3-Years
28%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Common Shares Outstanding
ÂĄ6.6B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
4%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Common Shares Outstanding
ÂĄ2.4B
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
4%
Imeik Technology Development Co Ltd
SZSE:300896
Common Shares Outstanding
ÂĄ301.3m
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
10.7B HKD
Industry
Biotechnology

Keymed Biosciences, Inc. is an investment holding company. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.

Intrinsic Value
37.36 HKD
Overvaluation 2%
Intrinsic Value
Price
K

See Also

What is KeyMed Biosciences Inc's Common Shares Outstanding?
Common Shares Outstanding
279.7m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Common Shares Outstanding amounts to 279.7m CNY.

What is KeyMed Biosciences Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
1%

Over the last year, the Common Shares Outstanding growth was 1%. The average annual Common Shares Outstanding growth rates for KeyMed Biosciences Inc have been 1% over the past three years .

Back to Top